2014骨质疏松指南解读ppt课件.ppt

2014NOF骨质疏松指南解读;epidemiology ;Medical Impact ;Pathogenesis of Osteoporosis-Related Fractures ;Risk Assessment ;Others ;T-Score;indication;椎体成像;UNIVERSAL RECOMMENDATIONS FOR ALL PATIENTS ;Adequate Intake of Calcium;Adequate Intake of Vitamin D ;Treatment of Vitamin D Deficiency;Regular Weight-Bearing and Muscle-Strengthening Exercise ;Fall Prevention ;Cessation of Tobacco Use and Avoidance of Excessive Alcohol Intake ;PHARMACOLOGIC THERAPY ;Pharmacologic treatment recommendations ;U.S. FDA-Approved Drugs for Osteoporosis;Bisphosphonates;双膦酸盐;Drug safety;Drug safety;Drug safety;Calcitonin;Drug safety;Estrogen/Hormone Therapy (ET/HT) ;Drug efficacy;Drug safety;Estrogen Agonist/Antagonist (formerly known as SERMs): Raloxifene ;Raloxifene; Tissue-Selective Estrogen Complex: Conjugated estrogens/ bazedoxifene (Conjugated estrogens paired with estrogen agonist/antagonist) ;Drug efficacy;Drug Administration ;Drug Safety: ;Parathyroid Hormone: Teriparatide ;Drug efficacy;Drug Administration;Drug safety:;Receptor Activator of Nuclear Factor kappa-B (RANK) Ligand (RANKL)/ RANKL Inhibitor: Denosumab;Drug administration and safety;Sequential and Combination Therapy;Duration of Treatment ;Thank you